Legoux, J.-L.; Faroux, R.; Barrière, N.; Le Malicot, K.; Tougeron, D.; Lorgis, V.; Guerin-Meyer, V.; Bourgeois, V.; Malka, D.; Aparicio, T.;
et al. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Cancers 2024, 16, 1515.
https://doi.org/10.3390/cancers16081515
AMA Style
Legoux J-L, Faroux R, Barrière N, Le Malicot K, Tougeron D, Lorgis V, Guerin-Meyer V, Bourgeois V, Malka D, Aparicio T,
et al. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Cancers. 2024; 16(8):1515.
https://doi.org/10.3390/cancers16081515
Chicago/Turabian Style
Legoux, Jean-Louis, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio,
and et al. 2024. "First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)" Cancers 16, no. 8: 1515.
https://doi.org/10.3390/cancers16081515
APA Style
Legoux, J.-L., Faroux, R., Barrière, N., Le Malicot, K., Tougeron, D., Lorgis, V., Guerin-Meyer, V., Bourgeois, V., Malka, D., Aparicio, T., Baconnier, M., Lebrun-Ly, V., Egreteau, J., Khemissa Akouz, F., Terme, M., Lepage, C., & Boige, V.
(2024). First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Cancers, 16(8), 1515.
https://doi.org/10.3390/cancers16081515